SlidesetViral Hepatitis and Liver DiseaseAnti-HBs Monoclonal Antibodes in Nuc-naïve and Combo Therapies - Carey Hwang, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseAre We Only Able to Suppress HDV or is Cure in Reach? - Pietro Lampertico, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseBalance of Response and Adverse Events in Immunotherapy for CHB - Jordan Feld, MD, MPHView Slideset
SlidesetViral Hepatitis and Liver DiseaseBepirovirsen in Combination with Peg-IFN and Other Molecules - Stuart Kendrick, MD, PhD, MRCPView Slideset
SlidesetViral Hepatitis and Liver DiseaseDiscrimination of Integrated vs. cccDNA Derived HBsAg - Chloe Thio, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseDoes siRNA Restore Host Control and Could it Lead to Sustained HBsAg Suppression? - Michael J. Sofia, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseDurability of Response After DAA Therapies - Fabien Zoulim, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseEfficacy and Safety of Targeting PD-L1 with Monoclonal Antibodies - Jinzi J. Wu, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseExpanding CHB Treatment Criteria with Nucs as Prelude of Novel Curative Therapies? - Harry Janssen, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseImmunological Profiles Induced by New Therapeutic Vaccines - Eleanor Barnes, PhD, FRCP, F Med SciView Slideset
SlidesetViral Hepatitis and Liver DiseaseLatest Updates on Novel Biomarkers in HBV Cure - Man-Fung Yuen, MBBS, MD, PhD, DScView Slideset
SlidesetViral Hepatitis and Liver DiseaseNext Generation CAMs, New Life for Small Molecules? - Mark Sulkowski, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseSecond Generation CAMs Leading to HBsAg Decline - Matthew McClure, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseValue of Adding Recombinant Antigens to Viral Vector Vaccines - Ventzi Vassilev, PhDView Slideset
